Dr Reddy's Laboratories (RDY) is disputing reports it plans to cut a significant portion of its workforce, with the India-based drug maker telling Indian regulators on Monday that a Business Standard report published overnight was "factually incorrect."
In a letter sent Monday to the National Stock Exchange of India, Kumar Singh, Dr Reddy's compliance officer, said it "categorically" denies the reported job actions, adding there is nothing happening at the company at this time that would typically trigger a disclosure.
The Business Standard report, citing multiple individuals with knowledge of the matter, said Dr Reddy recently began a "significant downsizing initiative" expected to reduce its workforce costs by 25%.
Dr Reddy shares recently was fractionally lower in US late-morning trading.
Price: 13.20, Change: -0.03, Percent Change: -0.19
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.